Briquilimab - Jasper Therapeutics
Alternative Names: AMG-191; JSP-191Latest Information Update: 25 Jun 2024
At a glance
- Originator Amgen; National Heart, Lung and Blood Institute; Stanford University
- Developer Amgen; Jasper Therapeutics; Tectonic Therapeutic
- Class Anti-inflammatories; Antianaemics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic urticaria
- Phase I Myelodysplastic syndromes
- Preclinical Anaphylaxis; Asthma; Atopic dermatitis; Fabry's disease; Gaucher's disease
- Discontinued Inflammation